Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over ...

Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda. Prosecutors Question Doctors About UnitedHealth's Medicare Billing Practices ...

The U.S. drug giant said that Verona’s Ohtuvayre, which treats chronic obstructive pulmonary disease, will strengthen its lineup of cardiovascular treatments.

Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...